Entries by Thomas Gabrielczyk

Evotec axes 400 jobs worldwide

After the drug discovery specialist Evotec SE lowered its annual forecast and lost almost 75% of its market capitalisation in just eight months, the new CEO, Christian Wojczewski, is taking action and closing non-profitable areas.

Nitrogenases also can fix CO2

Investigating substrate selectivity of nitrogenase enzymes in phototrophic R. capsulatus bacteria, German microbiologist have found one converting CO2 to formiate and methane opening the way to fossil oil-free hydrocarbon synthesis

Roche inks US$2bn biobucks deal with Sangamo

After Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.

BI Venture Funds invests in oncolytic bacteria

With an investment of its venture arm (BI-VF), Boehringer Ingelheim underlines its committment to expand the reach of cancer immune therapies. The Series A financing in Chinese Synthetica Pioneering that engineers oncolytic bacteria to deliver toxic payloads or modulators of the tumour environment to solid tumours follows an investment in T3 Pharmaceuticals.